PortfoliosLab logo
Zai Lab Ltd (9688.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

KYG9887T1168

Highlights

Market Cap

HK$25.87B

EPS (TTM)

-HK$0.24

Total Revenue (TTM)

HK$418.33M

Gross Profit (TTM)

HK$265.44M

Year Range

HK$12.32 - HK$32.50

Target Price

HK$38.22

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Zai Lab Ltd (9688.HK) returned 12.38% year-to-date (YTD) and 45.68% over the past 12 months.


9688.HK

YTD

12.38%

1M

8.26%

6M

-3.87%

1Y

45.68%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of 9688.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-0.48%27.27%7.14%-14.04%-3.67%12.38%
2024-21.67%1.19%-24.30%0.78%12.62%-8.47%11.19%2.28%24.80%25.66%-6.07%-6.46%-2.33%
202331.30%-13.00%-7.30%4.61%-5.14%-18.76%17.38%-15.01%-9.59%4.75%7.11%1.18%-12.60%
2022-31.90%18.51%-11.97%-8.34%-24.43%7.43%19.81%10.61%-22.71%-34.01%50.44%-9.56%-51.38%
202115.67%-7.36%-7.13%25.75%6.72%-1.23%-22.43%3.97%-23.73%-3.16%-30.83%-9.96%-51.06%
20205.08%0.62%28.99%24.28%69.51%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 84, 9688.HK is among the top 16% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 9688.HK is 8484
Overall Rank
The Sharpe Ratio Rank of 9688.HK is 7979
Sharpe Ratio Rank
The Sortino Ratio Rank of 9688.HK is 8484
Sortino Ratio Rank
The Omega Ratio Rank of 9688.HK is 8484
Omega Ratio Rank
The Calmar Ratio Rank of 9688.HK is 8383
Calmar Ratio Rank
The Martin Ratio Rank of 9688.HK is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Zai Lab Ltd (9688.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Zai Lab Ltd Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: 0.77
  • All Time: -0.25

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Zai Lab Ltd compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Zai Lab Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Zai Lab Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Zai Lab Ltd was 92.94%, occurring on Apr 18, 2024. The portfolio has not yet recovered.

The current Zai Lab Ltd drawdown is 84.31%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.94%Jan 22, 2021795Apr 18, 2024
-13.09%Oct 14, 202014Nov 3, 20207Nov 12, 202021
-4.53%Dec 2, 20207Dec 10, 20204Dec 16, 202011
-3.35%Jan 5, 20213Jan 7, 20211Jan 8, 20214
-3.26%Dec 28, 20203Dec 30, 20201Dec 31, 20204

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Zai Lab Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Zai Lab Ltd, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 92.7% positive surprise.


-12.00-10.00-8.00-6.00-4.00-2.000.0020212022202320242025
-0.04
-0.55
Actual
Estimate

Valuation

The Valuation section provides an overview of how Zai Lab Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for 9688.HK relative to other companies in the Biotechnology industry. Currently, 9688.HK has a P/S ratio of 64.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for 9688.HK in comparison with other companies in the Biotechnology industry. Currently, 9688.HK has a P/B value of 3.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items